NAD+ and Epithalon are often grouped under the same longevity banner, but they target different aging clocks. NAD+ is best understood through mitochondrial capacity, redox state, and NAD-dependent signaling. Epithalon is best understood through telomere and telomerase-related aging questions. One is about how well the cell functions. The other is about how long the cell can keep dividing cleanly.

NAD+ benefits from a broader, more international evidence base. Epithalon is narrower and more concentrated in a specific lineage of telomere research. That does not make Epithalon unimportant. It makes the two compounds useful for different levels of confidence and different levels of specificity.

The combination rationale is straightforward: if one compound addresses mitochondrial decline and the other addresses telomere-linked decline, a multi-hallmark protocol may be more informative than a single-hallmark design. Whether that produces additive or synergistic results remains an open research question.